Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

Also called NCT02053909

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 250 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02053909
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02053909. Randomized; quadruple masking; primary purpose prevention. Start 2014-09 (registry gives no type); primary completion 2020-08 (actual). Results posted on 2022-09-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Acronym
TARGET
Condition
Saphenous Vein Graft Disease
Intervention (Drug)
Aspirin
Intervention (Drug)
Ticagrelor
Lead sponsor
Boca Raton Regional Hospital (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
Ottawa Heart Institute Research Corporation (class: other)

Record details

Record id
cardio:ct-nct02053909
Content hash
a1580ae9fade3d2ffd54959f1c810863ca505e5c663e074ad79aeb5a82af2c2f